T-DXd Effective in Some With HER2+ Breast Cancer

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
Medscape Medical News

source https://www.medscape.com/viewarticle/trastuzumab-deruxtecan-shows-promise-her2-bc-brain-2024a1000gq3?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?